<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820079</url>
  </required_header>
  <id_info>
    <org_study_id>ADX10059-204</org_study_id>
    <secondary_id>2008-005104-10</secondary_id>
    <nct_id>NCT00820079</nct_id>
  </id_info>
  <brief_title>ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)</brief_title>
  <official_title>A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addex Pharma S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addex Pharma S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal
      reflux.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of GERD symptom free days in week 2 of study medication treatment</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GERD symptoms</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep disturbance</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antacid rescue medication</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of GERD</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on lower oesophageal sphincter and reflux episodes</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>ADX10059 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice-daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADX10059 Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twice-daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX10059</intervention_name>
    <description>oral administration</description>
    <arm_group_label>ADX10059 120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX10059 Matching Placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>ADX10059 Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of typical GERD

          -  well controlled on a standard clinical symptoms controlled dose of PPI treatment

          -  body mass index â‰¤32 kg/m2

        Exclusion Criteria:

          -  exclusively atypical symptoms of GERD

          -  symptoms that have been shown not to be associated with GERD

          -  erosive oesophagitis

          -  hiatus hernia &gt; 3 cm

          -  current diagnosis of co-existing psychiatric disease

          -  known clinically significant allergy or known hypersensitivity to drugs

          -  pregnant or breast-feeding

          -  has received sodium valproate or topiramate within 30 days of Screening

          -  has a history of a significant medical condition that may affect the safety of the
             patient or preclude adequate participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gorlitz</name>
      <address>
        <city>Gorlitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madgeburg 12</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magdeburg 13</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <last_update_submitted>December 23, 2009</last_update_submitted>
  <last_update_submitted_qc>December 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Addex Pharma SA</organization>
  </responsible_party>
  <keyword>Gastroesophageal reflux</keyword>
  <keyword>Heartburn</keyword>
  <keyword>Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

